Literature DB >> 12503906

Depressive symptoms among amphetamine and cocaine users before and after substance abuse treatment.

Kara S Riehman1, Martin Y Iguchi, M Douglas Anglin.   

Abstract

This study examined whether higher rates of depressive symptoms among amphetamine compared with cocaine users result from amphetamine use itself, polydrug use, or experiencing a major lifetime depressive episode and whether depressive symptoms among amphetamine users are more likely to persist 12 months after treatment. The association between amphetamine use and depressive symptoms disappears when controlling for polydrug use and lifetime major depressive episode. Polydrug use and lifetime depressive episode are significantly related to depressive symptoms in the year preceding treatment. Amphetamine use at intake does not predict depressive symptoms among individuals who are abstinent at follow-up, and amphetamine users are no more likely than cocaine users to report depression at a 12-month follow-up.

Entities:  

Mesh:

Year:  2002        PMID: 12503906     DOI: 10.1037//0893-164x.16.4.333

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  4 in total

1.  Anhedonia and amotivation in psychiatric outpatients with fully remitted stimulant use disorder.

Authors:  Adam M Leventhal; Christopher W Kahler; Lara A Ray; Kristen Stone; Diane Young; Iwona Chelminski; Mark Zimmerman
Journal:  Am J Addict       Date:  2008 May-Jun

2.  Predictors of depressive symptomatology among rural stimulant users.

Authors:  Raminta Daniulaityte; Russel Falck; Jichuan Wang; Robert G Carlson; Carl G Leukefeld; Brenda M Booth
Journal:  J Psychoactive Drugs       Date:  2010-12

3.  Meta-analysis of depression and substance use and impairment among cocaine users.

Authors:  Kenneth R Conner; Martin Pinquart; Amanda P Holbrook
Journal:  Drug Alcohol Depend       Date:  2008-06-27       Impact factor: 4.492

4.  Axis I and II disorders as long-term predictors of mental distress: a six-year prospective follow-up of substance-dependent patients.

Authors:  Kjell Bakken; Anne Signe Landheim; Per Vaglum
Journal:  BMC Psychiatry       Date:  2007-06-26       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.